Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis

In clinical practice, interruption of treatment may not result in immediate cessation of disease control, and some patients even experience sustained treatment response following treatment interruption. This post hoc analysis of UNCOVER-1 and -2 Phase 3 clinical trials characterized the time to loss...

Descripción completa

Detalles Bibliográficos
Autores principales: PAPP, Kim, PAUL, Carle, KLEYN, C. Elise, HUANG, Yu-Huei, TSAI, Tsen-Fang, SCHUSTER, Christopher, EL BAOU, Celine, TOTH, Agoston, RIEDL, Elisabeth, MROWIETZ, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574691/
https://www.ncbi.nlm.nih.gov/pubmed/35170742
http://dx.doi.org/10.2340/actadv.v102.1984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574691/
https://www.ncbi.nlm.nih.gov/pubmed/35170742
http://dx.doi.org/10.2340/actadv.v102.1984

Ejemplares similares